Kava hepatotoxicity in traditional and modern use: The presumed Pacific kava paradox hypothesis revisited

British Journal of Clinical Pharmacology

Volumn 73, Issue 2, 2012, Pages 170-174

  Teschke, Rolf ^a   Sarris, Jerome ^b,c   Schweitzer, Isaac ^b  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c SWINBURNE UNIVERSITY OF TECHNOLOGY   (Australia)

Author keywords

Drug induced liver injury; Herb induced liver injury; Herbal hepatotoxicity; Kava; Kava hepatotoxicity; Piper methysticum

Indexed keywords

ACETONE; ALCOHOL; KAVA; KAVA EXTRACT; TOXIN;

ANXIETY; ARTICLE; AUSTRALIA; GERMANY; HUMAN; HYPOTHESIS; LIVER TOXICITY; MOULD; NONHUMAN; PIPER METHYSTICUM; PRIORITY JOURNAL; RECREATION; RHIZOME; TRADITIONAL MEDICINE; UNITED STATES;

DRUG-INDUCED LIVER INJURY; HUMANS; KAVA; LIVER; PACIFIC ISLANDS; PLANT EXTRACTS; QUALITY CONTROL; RHIZOME; RISK FACTORS;

EID: 84855489838     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2011.04070.x     Document Type: Article

References (35)

1. WHO (World Health Organization). Assessments of the Risk of Hepatotoxicity with Kava Products. Geneva, Switzerland: WHO Document Production Services, 2007.
2. Teschke R, Schulze J. Risk of kava hepatotoxicity and the FDA consumer advisory. J Am Med Assoc 2010; 304: 2174-5.
3. Lebot V, Merlin M, Lindstrom L. Kava, the Pacific Elixir. New Haven, CT: Yale University Press, 1997.
4. Therapeutic Goods Administration (TGA). Australian Government, Department of Health and Aging. Kava fact sheet. April 2005. Web page last updated September 20, 2010. Available at: (last accessed 21 June 2011).
5. Sarris J, Kavanagh DJ, Byrne G, Bone KM, Adams J, Deed G. The Kava Anxiety Depression Spectrum Study (KADSS): a randomized, placebo-controlled crossover trial using an aqueous extract of Piper methysticum. Psychopharmacology 2009; 205: 399-407.
6. Currie BJ, Clough AR. Kava hepatotoxicity with Western herbal products: does it occur with traditional kava use? Med J Aust 2003; 178: 421-2.
7. Moulds RFW, Malani J. Kava: herbal panacea or liver poison? Med J Aust 2003; 178: 451-3.
8. Teschke R, Gaus W, Loew D. Kava extracts: safety and risks including rare hepatotoxicity. Phytomedicine 2003; 10: 440-6.
9. FDA (U.S. Food and Drug Administration). Consumer advisory: kava-containing dietary supplements may be associated with severe liver injury. Issued March 25, 2002. Available at: (last accessed 21 June 2011).
10. Danan G, Bénichou C. Causality assessment of adverse reactions to drugs - I. A novel method based on the conclusions of international consensus meetings: application to drug-induced liver injuries. J Clin Epidemiol 1993; 46: 1323-30.
11. Teschke R, Schwarzenboeck A, Hennermann KH. Causality assessment in hepatotoxicity by drugs and dietary supplements. Br J Clin Pharmacol 2008; 66: 758-66.
12. Teschke R, Schwarzenboeck A, Hennermann KH. Kava hepatotoxicity: a clinical survey and critical analysis of 26 suspected cases. Eur J Gastroenterol Hepatol 2008; 20: 1182-93.
13. Teschke R. Kava hepatotoxicity - a clinical review. Ann Hepatol 2010; 9: 251-65.
14. Mathews JD, Riley MD, Fejo L, Munoz E, Milns NR, Gardner ID, Powers JR, Ganygulpa E, Gununuwawuy BJ. Effects of the heavy usage of kava on physical health: summary of a pilot survey in an aboriginal community. Med J Aust 1988; 148: 548-55.
15. Clough AR, Bailie RS, Currie B. Liver function test abnormalities in users of aqueous kava extracts. J Toxicol Clin Toxicol 2003; 41: 821-9.
16. Clough AR, Jacups SP, Wang Z, Burns CB, Bailie RS, Carney SJ, Collie A, Guyula T, McDonald SP, Currie BJ. Health effects of kava use in an eastern Arnhem Land community. Intern Med 2003; 33: 336-40.
17. Russmann S, Barguil Y, Cabalion P, Kritsanida M, Duhet D, Lauterburg BH. Hepatic injury due to traditional aqueous extracts of kava root in New Caledonia. Eur J Gastroenterol Hepatol 2003; 15: 1033-6.
18. Brown AC, Onopa JO, Holck P, Kaufusi P, Kabasawa D, Craig WJ, Dragull K, Levine AM, Baker JD. Traditional kava beverage consumption and liver function tests in a predominantly Tongan population in Hawaii. Clin Toxicol 2007; 45: 549-56.
19. Gow PJ, Connelly NJ, Hill RL, Crowley P, Angus PW. Fatal fulminant hepatic failure induced by a natural therapy containing kava. Med J Aust 2003; 178: 442-3.
20. Humberston CL, Akhtar J, Krenzelok EP. Acute hepatitis induced by kava kava. J Toxicol Clin Toxicol 2003; 41: 109-13.
21. Teschke R, Genthner A, Wolff A. Kava hepatotoxicity: comparison of aqueous, ethanolic, acetonic kava extracts and kava-herbs mixtures. J Ethnopharmacol 2009; 123: 378-84.
22. Teschke R, Sarris J, Glass X, Schulze J. Kava, the anxiolytic herb: back to basics to prevent liver injury? Br J Clin Pharmacol 2011; 71: 445-8.
23. Teschke R, Qiu SX, Xuan TD, Lebot V. Kava and kava hepatotoxicity: requirements for novel experimental, ethnobotanical, and clinical studies based on a review of the evidence. Phytother Res 2011 (in press) DOI: 10.1002/ptr.3464.
24. Ernst E. A re-evaluation of kava (Piper methysticum). Br J Clin Pharmacol 2007; 64: 415-7.
25. Richardson WN, Henderson L. The safety of kava - a regulatory perspective. Br J Clin Pharmcol 2007; 64: 418-20.
26. Teschke R, Lebot V. Proposal for a kava quality standardization code. Food Chem Toxicol 2011 (in press) DOI: 10.1016/j.fct.2011.06.075.
27. Teschke R. Kava hepatotoxicity: pathogenetic aspects and prospective considerations. Liver Int 2010; 30: 1270-9.
28. Teschke R, Qiu SX, Lebot V. Herbal hepatotoxicity by kava: update on pipermethystine, flavokavain B, and mould hepatotoxins as primarily assumed culprits. Dig Liv Dis 2011; 43: 657-81 DOI: 10.1016/j.dld.2011.01.018.
29. Kandukuru P, Huang AS, Dong J, Bittenbender HC, Li Y. Rapid identification of bacterial isolates from aqueous kava (Piper methysticum) extracts by polymerase chain reaction and DNA sequencing. Applied Microbiol 2009; 49: 764-8.
30. Trucksess M, Weaver C, Oles C, D'Ovidio K, Rader J. Determination of aflatoxins and ochratoxin A in ginseng and other botanical roots by immunoaffinity column cleanup and liquid chromatography with fluorescence detection. J AOAC Int 2006; 89: 624-30.
31. Weaver CM, Trucksess MW. Determination of aflatoxins in botanical roots by a modification of AOAC Official Method 991.31: single-laboratory validation. J AOAC Int 2010; 93: 184-9.
32. Krishnamachari KA, Bhat RV, Nagarajan V, Tilak TB. Hepatitis due to aflatoxicosis. An outbreak in Western India. Lancet 1975; 7915: 1061-3.
33. Ngindu A, Johnson BK, Ngira JA, Nandwa H, Jansen AJ, Kaviti JN, Siongok TA. Outbreak of acute hepatitis caused by aflatoxin poisoning in Kenya. Lancet 1982; 319: 1346-8.
34. Tandon HD, Tandon BN, Ramalingaswami V. Epidemic of toxic hepatitis in India of possible mycotoxic origin. Arch Pathol Lab Med 1978; 102: 372-6.
35. Olsen LR, Grillo MP, Skonberg C. Constituents in kava extracts potentially involved in hepatotoxicity: a review. Chem Res Toxicol 2011 (in press) DOI: 10.1021/tx100412m.